Immunic Inc. (IMUX) PT Raised to $61 at BMO Capital, Following Drug Trial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts IMUX Hot Sheet
Price: $7.94 +4.47%
Rating Summary:
17 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
17 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
BMO Capital analyst George Farmer raised the price target on Immunic Inc. (NASDAQ: IMUX) to $61.00 (from $40.00) while maintaining a Market Perform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Immunic to Participate in Investor Conferences in November
- Top E-Commerce Stock Pick from BMO Capital Markets
- Procore Technologies, Inc (PCOR) PT Raised to $90 at BTIG
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
